Insider Buying: Oxford BioMedica plc (OXB) Insider Purchases 388 Shares of Stock

Share on StockTwits

Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 388 shares of Oxford BioMedica stock in a transaction dated Thursday, May 23rd. The stock was bought at an average cost of GBX 689 ($9.00) per share, with a total value of £2,673.32 ($3,493.17).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Thursday, April 25th, Lorenzo Tallarigo purchased 379 shares of Oxford BioMedica stock. The stock was bought at an average cost of GBX 706 ($9.23) per share, with a total value of £2,675.74 ($3,496.33).
  • On Monday, March 25th, Lorenzo Tallarigo purchased 382 shares of Oxford BioMedica stock. The stock was bought at an average cost of GBX 695 ($9.08) per share, with a total value of £2,654.90 ($3,469.10).
  • On Monday, February 25th, Lorenzo Tallarigo purchased 413 shares of Oxford BioMedica stock. The stock was bought at an average cost of GBX 644 ($8.42) per share, with a total value of £2,659.72 ($3,475.40).

OXB opened at GBX 690 ($9.02) on Monday. The firm has a market capitalization of $475.16 million and a PE ratio of 63.30. The company has a debt-to-equity ratio of 118.46, a current ratio of 2.44 and a quick ratio of 2.26. Oxford BioMedica plc has a 12 month low of GBX 581 ($7.59) and a 12 month high of GBX 1,062.60 ($13.88).

Separately, Peel Hunt reissued a “buy” rating on shares of Oxford BioMedica in a research report on Tuesday, March 12th.

TRADEMARK VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4353584/insider-buying-oxford-biomedica-plc-oxb-insider-purchases-388-shares-of-stock.html.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Recommended Story: How Does the Quiet Period Work?

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report